Skip to content

Checked

Class IIIDrug recallOngoing

Nilotinib Capsules recall

Recalled by Cipla USA, Inc. of Warren, NJ · FDA report 03/11/2026

Not an official recall notice and may be delayed. Confirm with the manufacturer or the agency.

Class
Class III
Low risk
Status
Ongoing
Recall started
02/18/2026
Distribution
Nationwide

Reason for recall

Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.

Class III: Use of or exposure to the product is not likely to cause adverse health consequences.

Recalled product

Product
Nilotinib Capsules, 150 mg per capsule, packaged in cartons, Rx only, Manufactured by: Cipla Ltd., Verna, Goa, India, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, Outer carton: 112 capsules (4 individual packs containing 28 capsules each) NDC 69097-031-74; Inner carton: 28 capsules (4 blisters of 7 capsules) NDC 69097-031-56; Foil blister: NDC 69097-031-17
Lot and code info
Lot #: 5GJ0220, 5GJ0221, 5GJ0222, Exp 04/30/2027
Quantity
271 cartons - Ex: 84 outer cartons x 4 inner cartons x 4 blisters x 7 capsules
Recall number
D-0381-2026
Event ID
98452
Initiated by
Voluntary: Firm initiated

Where it was distributed

U.S.A. Nationwide

  • Nationwide

Recall timeline

  1. 02/18/2026Firm started the recall
  2. 03/03/2026FDA classified it as Class III
  3. 03/11/2026Published in the FDA enforcement report

All products in this recall

2 products under event 98452

More recalls from Cipla USA

Frequently asked questions

Why was Nilotinib Capsules recalled?
Failed Tablet/Capsule Specifications: Observed OOS results at 6-months long-term stability condition for Description test and Appearance by Visual Inspection test.
What does Class III mean?
Class III is FDA's low risk recall category: use of or exposure to the product is not likely to cause adverse health consequences.
Where was the recalled product sold?
U.S.A. Nationwide
Is this recall still active?
The FDA lists the recall as ongoing. The recall is still in progress.

Source: U.S. Food and Drug Administration, openFDA enforcement report · Last updated 03/11/2026 · Do not rely on openFDA to make decisions regarding medical care